Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leadin
资讯
2024-11-15
MEDIA RELEASE
Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)
One of several biosimilar value drivers for Sandoz
...